Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy

Urology

Volumn 51, Issue 5, 1998, Pages 687-692

  Engel, Jason D ^a   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEXUAL INTERCOURSE; TRANSURETHRAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; COITUS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; IMPOTENCE; INJECTIONS; MALE; MIDDLE AGED; PAIN; PAPAVERINE; PATIENT SATISFACTION; PENILE ERECTION; PENIS; PHENTOLAMINE; PLACEBOS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URETHRA; VASODILATOR AGENTS;

EID: 0031744486     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00093-4     Document Type: Article

References (18)

1. Brindley GS. Cavernosal alpha blockade, a new technique for investigating and treating erectile impotence. Br J Psych. 143:1983;332-337.
2. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. 2:1982;938.
3. Robinette MA, Moffat MJ. Intracorporal injection of papaverine and phentolamine in the management of impotence. Br J Urol. 58:1986;692-695.
4. Kursh ED, Bodner DR, Resnick MI, Althof SE, Turner L, Risen C, Levine SB. Injection therapy for impotence. Urol Clin North Am. 15:1988;625-629.
5. Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence 8-year experience with 615 cases . J Urol. 145:1991;287-293.
6. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 22:1995;833-845.
7. Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kubot Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M, Shirai M. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol. 141:1989;323-325.
8. Waldhauser M, Schramed P. Efficacy and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol. 140:1988;525-528.
9. Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH. Clinical guidelines panel on erectile dysfunction summary report on the treatment of organic erectile dysfunction . J Urol. 156:1996;2007-2011.
10. Porst H. The rationale for prostaglandin E1 in erectile failure a survey of worldwide experience . J Urol. 155:1996;802-815.
11. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology. 43:1994;84-87.
12. Weiss JN, Ravalli R, Brettschneider N, Badlani GH. Reasons for high drop-out rates with self-injection therapy for impotence. Int J Impotence Res. 6:1994;171-174.
13. Flynn RJ, Williams G. Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamine. Br J Urol. 78:1996;628-631.
14. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, Resnick MI. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther. 15:1989;121-129.
15. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky R, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 336:1997;1-7.
16. Valdevenito R, Melman A. Intracavernous self-injection pharmacotherapy program analysis of results and complications . Int J Impotence Res. 6:1994;81-91.
17. McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, Lange JL, McClennan BL, Mebust WK, Reilly NJ, Roberts RG, Sacks SA, and Wasson JH: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research Clinical Practice Guidelines - Quick Reference Guide for Clinicians, No. 8, February 1994, pp 1-17.
18. Linet O, and Ogring F, on behalf of the Alprostadil Study Group: Efficacy and safety of intra-cavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334: 873-877, 1996.